Throughout my scholarly journey, I have participated in numerous projects, honing my skills in comparative genomics, bioinformatics, microbial genetics, and molecular biology. My extensive training encompasses the analysis of defense and antibiotic resistance genes , as well as pathogenicity islands  within large-scale bacterial genomic and metagenomic data, utilizing a variety of bioinformatic and computational tools. My research findings have been published in high-impact, peer-reviewed journals such as the Philosophical Transactions of the Royal Society B, Nature Communications, and Nucleic Acids Research. I have also completed an international course at the Pasteur Institute in France, focusing on the analysis of TnSeq, RNASeq, and functional genomics. As a junior faculty member at the University of Dhaka, Bangladesh (2014-2017), I was awarded two early career research grants and actively involved undergraduates in both projects.

My particular interest lies in translational research, specifically utilizing microbial systems for therapeutic medicine. During my postdoctoral fellowship at the National Institutes of Health (NIH) in Bethesda, USA, I participated in a project that addressed disease-associated genomic instability using fission yeast as a model organism. I contributed to the development of a CRISPR toolkit to modulate fission yeast, which will aid in studying genetic mutations related to cancer, obesity, and aging. Prior to this, I completed another postdoctoral fellowship at Cornell University, USA, where I computationally analyzed various transposable DNA elements associated with antibiotic resistance and investigated their potential in genome editing. My work focused on Acinetobacter baumannii, a major global threat of nosocomial infection and a “priority pathogen” as designated by the World Health Organization (WHO), necessitating research and development for new antibiotics.

I am driven to collaborate and establish my own research group, which will explore various bacterial mechanisms contributing to pathogenicity (e.g., biofilm formation, multi-drug resistance), genomic instability (e.g., cancer progression), and the design of therapeutic phages for early disease detection and personalized medicine.